(Q44176817)

30 November 2017

title

Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience (English)

1 reference

30 November 2017

1 reference

2

C Twelves

1 reference

30 November 2017

R C F Leonard

1

1 reference

30 November 2017

J Breddy

3

1 reference

30 November 2017

A Chaturvedi

4

1 reference

30 November 2017

A Hutcheon

5

1 reference

30 November 2017

R Salazar

6

1 reference

30 November 2017

D Cameron

7

1 reference

30 November 2017

publication date

1 October 2002

1 reference

European Journal of Cancer

30 November 2017

published in

1 reference

30 November 2017

volume

38

1 reference

30 November 2017

issue

15

1 reference

30 November 2017

page(s)

2020-2024

1 reference

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900238-1

7 January 2021

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900238-1

7 January 2021

Clinical experience of capecitabine in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900238-1

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900238-1

7 January 2021

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900238-1

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900238-1

7 January 2021

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900238-1

7 January 2021

Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900238-1

7 January 2021

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900238-1

7 January 2021

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900238-1

7 January 2021

10.1016/S0959-8049(02)00238-1

Identifiers

DOI

1 reference

30 November 2017

1 reference